Sudden deaths to be declared notifiable disease in Karnataka amid scare over Covid-19 vaccines
Addressing a news conference on Monday, Karnataka Health and Family Welfare Minister Dinesh Gundu Rao said the government would start monitoring sudden deaths reported among those below the age of 45.
The decision has been taken based on the recommendations submitted by an expert committee formed under Dr C N Ravindranath, Director, Sri Jayadeva Institute of Cardiovascular Sciences and Research, to investigate sudden cardiovascular events, including heart attacks and cardiac deaths, and their possible links to Covid-19 vaccines. The committee, however, found no causal link between the vaccines and cardiac deaths among the youth.
'Sudden deaths will be a notifiable disease. If someone dies outside a hospital suddenly, it should be reported to the government. Autopsy will also be compulsory to ascertain the cause of death,' Rao said, adding that the Health and Family Welfare Department would issue directions for the same.
On speculation that the vaccines were linked to cardiac deaths, he said that there were complaints about mRNA vaccines causing myocarditis in some cases. 'However, none from the country was administered with it,' the minister said, adding that the Covid-19 vaccines helped save lives.
Dr Ravindranath, who was also present at the news conference, said that there was a five to six per cent increase in cardiac deaths post-Covid, which he attributed to a change in risk factors for cardiac diseases due to altered lifestyle since the pandemic. 'Cardiac deaths are not caused by just one reason. It is multifactorial,' he said, adding that more than 50 per cent of the cases were caused due to smoking.
Referring to a meta-analysis carried out by scientists on those affected by Covid-19, he said that 20 per cent of the patients who recovered continued to face fatigue, insomnia, depression, anxiety, and breathing problems. 'But there were no heart attacks or cardiac-related diseases,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
New Covid Variant XFG Explained: Symptoms, Spread & Safety Tips You Need To Know
Last Updated: Symptoms mirror Omicron's, that is, fever, cough, fatigue, sore throat, and muscle aches. Though India's Covid response offers a foundation, but XFG demands targeted strategies As India navigates a post-Covid world, a new Omicron subvariant, XFG ('Stratus"), is raising concerns with its rapid spread and immune-evasive traits. First detected in Canada, XFG has reached 38 countries, including India, where it accounts for a growing share of cases. With India's active Covid-19 cases at 7,000 as of June 2025, per the Union Health Ministry, let's examine XFG's characteristics, India-specific data, and how the nation can prepare for this and future pandemics, drawing lessons from long Covid. What Is The XFG Variant? XFG, a recombinant subvariant of Omicron, emerges from the fusion of LF.7 and LP.8.1.2 strains, formed when two variants infect a person simultaneously, mixing genetic material. A Lancet study highlights four key spike protein mutations—His445Arg, Asn487Asp, Gln493Glu, and Thr572Ile—enabling 'strong immune evasion," allowing XFG to bypass antibodies from prior infections or vaccines. Globally, XFG accounts for 22.7% of sequenced cases as of June 2025, up from 7.4% a month earlier, per GISAID (Global Initiative on Sharing All Influenza Data), and may soon dominate over NB.1.8.1 ('Nimbus"), per The Conversation. In India, it's the dominant strain in Madhya Pradesh, with 63.6% of sequenced samples, per AIIMS Bhopal. Symptoms mirror Omicron's, that is, fever, cough, fatigue, sore throat, and muscle aches. However, XFG uniquely causes hoarseness—a scratchy or raspy voice—reported by doctors as a key marker, per Everyday Health. Unlike JN.1, which caused low-grade fever and digestive issues, XFG's symptoms are mild to moderate, with no evidence of increased severity or hospitalisation rates, per WHO. Current vaccines, targeting JN.1, remain effective against severe disease, and antivirals like Paxlovid and remdesivir work, per Time. How Many XFG Cases Have India Reported? India has reported 206 XFG cases as of June 11, per INSACOG, with Maharashtra leading at 89 cases, followed by West Bengal (49), Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh (6 each), Odisha (4), Puducherry (3), Delhi, Rajasthan, and Punjab (2 each), and Telangana and Haryana (1 each), per The Hindu. Of these, 159 cases were detected in May, with two each in April and June, indicating a rapid rise. India's active Covid-19 cases reached 7,000 by June 11, with Kerala reporting the highest active cases (2,200), followed by Gujarat (1,223) and Delhi (757). A 2024 ICMR survey notes 66% of respiratory viral infections in India are Covid-related, but hospitalisations remain low, News18 reported. AIIMS Bhopal's genomic analysis of 44 samples from May-June found XFG dominant in 28 (63.6%), with no NB.1.8.1 detected in Madhya Pradesh, highlighting regional variation. Dr Rajiv Behl, ICMR Director General, stresses XFG's low severity but urges vigilance for vulnerable groups—those over 70 or with comorbidities. Why XFG Matters To India India's 1.4 billion population and $3 trillion economy face significant risks from new variants. Long Covid, affecting 7% of India's 44 million Covid cases (3 million people), costs 1% of GDP annually, per a 2024 NITI Aayog estimate, with 40% reporting fatigue and 25% brain fog. XFG's immune evasion could exacerbate this. Rural areas, with only 10% of health centres offering post-Covid care, face worse outcomes, per The Indian Express. A 2024 Times of India poll shows only 25% of Indians know about long Covid, limiting XFG awareness. Vaccine hesitancy, at 30% in rural India, and low Omicron-specific booster uptake (18%) weaken defences, per ICMR 2024. With 74 Covid deaths in 2025, mostly among the elderly and immunocompromised, XFG's spread threatens vulnerable groups. How India Should Prepare India's Covid response—2.2 billion vaccine doses by 2025—offers a foundation, but XFG demands targeted strategies: Enhanced Genomic Surveillance: INSACOG's 54 labs must expand sequencing, as only 0.1% of cases are sequenced, per The Hindu. AIIMS Bhopal's model, detecting XFG in 63.6% of samples, shows the value of regional labs. Scaling Truenat and RT-PCR testing to 80% of health centers, especially rural ones, could detect variants early, per Dr Balram Bhargava, a renowned cardiologist and public health leader. Vaccination & Boosters: Only 18% of Indians have Omicron-specific boosters. A 2025 campaign targeting 50% booster coverage, especially for those over 70, could cut severe cases by 30%, per WHO. Mobile vaccination units, successful in 2021, should reach rural areas. Hospital Preparedness: Only 50% of health centres have ventilators, and 30% lack oxygen, per a 2024 MoHFW report. The Centre's 2025 mock drills must ensure 75% of 1.5 lakh centers have isolation beds and antivirals, costing Rs 5,000 crore. Telemedicine, used by 15% of urban Indians, can expand to rural areas. Masking and Ventilation: XFG's spread in crowded spaces, like Mumbai's trains, requires masks and improved ventilation. A 2023 Singapore study cut transmission by 20% with air purifiers. India's public buildings need similar upgrades. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! tags : covid symptoms Long COVID omicron view comments Location : New Delhi, India, India First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
The Print
an hour ago
- The Print
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. New Delhi, Jul 12 (PTI) People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. 'But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment,' Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India,' said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. 'We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed,' said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. 'India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care,' Rizwan said. PTI PLB SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
an hour ago
- Time of India
XFG 'Stratus' COVID-19 variant spreading fast: One unique symptom that distinguishes it from others
The world may have moved on from the harshest days of the pandemic, but the virus hasn't quite left the stage. A new Covid-19 variant, named XFG and nicknamed 'Stratus', is making headlines globally. With a noticeable rise in cases, which has been detected in 38 countries, experts are keeping a close watch. The World Health Organisation (WHO) has officially placed Stratus under its list of Variants Under Monitoring (VUM). What makes this variant different? How severe is it? And what symptoms are being observed so far? Here's all we need to know about the new variant. What is the Stratus (XFG) variant? Stratus is a recombinant subvariant of the Omicron lineage, meaning it's a blend formed when a person is infected with two different Covid strains at the same time. Specifically, Stratus is a hybrid of LF.7 and LP.8.1.2, two other Omicron subvariants. Recombinant strains like this typically begin with the letter X, hence the name XFG. What sets Stratus apart is its mutations in the spike protein, the part of the virus that helps it latch onto human cells. According to a Lancet report and data shared via the GISAID platform, this variant has been found in over 38 countries as of late June 2025, with nearly 1,648 genome sequences submitted globally. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Upto 15% Discount for Salaried Individuals ICICI Pru Life Insurance Plan Get Quote Undo Despite this spread, it's important to note: the WHO has assessed the global public health risk of Stratus as low, which means there's no current indication that it causes more severe illness than previous strains. Symptoms to know: Is Stratus showing new signs? What makes the Stratus variant stand out symptom-wise isn't how severe it is, but how subtly different it behaves. Much like earlier Omicron variants, symptoms are generally mild, especially in people who are vaccinated. However, one particular symptom is drawing attention, which is the hoarseness or a raspy voice. This symptom has emerged more frequently in Stratus cases than in other recent Covid variants. It's thought to be due to the way this variant targets the upper respiratory tract. Other mild symptoms observed include: Scratchy throat Nasal congestion Fatigue Low-grade fever Muscle aches But unlike earlier strains, loss of smell or taste is seen to be less common with Stratus. Still, symptoms can differ from one person to another. Testing remains key to confirming the infection. Spread and immune evasion : Why Stratus is under watch One of the reasons scientists are closely examining Stratus is its ability to bypass the immune system. The changes in its spike protein allow it to partially avoid antibodies from previous infections or vaccines. This is not proof that immunisations are ineffective; WHO verifies that current vaccines continue to protect against serious disease and hospitalisation, even with Stratus in circulation. However, the virus can still cause illnesses, particularly in crowded or poorly ventilated environments. Caution is always wise, but panic isn't supported by current data.
